Form 4: Arcutis Director Sells Shares After Option Exercise

Arcutis Biotherapeutics Director Howard G. Welgus exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions on October 1, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026.
• Welgus exercised stock options to acquire 9,538 shares of common stock at an exercise price of $1.6806 per share.
• Concurrently, he sold 9,538 shares of common stock at a weighted average price of $18.9227 per share, with prices ranging from $18.84 to $19.038.
• An additional 462 shares of common stock were sold at the same weighted average price of $18.9227 per share.
• Following these transactions, Welgus beneficially owns 99,744 shares of Arcutis Biotherapeutics common stock.
• The exercised stock option was fully vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, these transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned personal financial event rather than a reaction to new company-specific information. The director also realized a significant profit from the option exercise.

Positives

• The director realized a significant profit by exercising options at $1.6806 and selling shares at a weighted average price of $18.9227.

Negatives

• The sale of shares by a director, even under a pre-arranged plan, reduces their direct ownership stake in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for a publicly traded company in the biotechnology sector. It reflects a director's personal financial planning rather than a direct statement on industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, though the planned nature of the sale mitigates concerns about management's confidence.

Next Steps

• The Rule 10b5-1 trading plan under which these transactions occurred is scheduled to end on May 29, 2026, implying potential future transactions under this plan until that date.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 trading plan. Such planned sales by a director typically do not indicate a change in the company's fundamental outlook or warrant a significant shift in investment strategy. Investors should consider broader company performance and market conditions rather than this single, planned insider transaction.

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction